CENTENNIAL (S&P Global Ratings) May 25, 2018–S&P Global Ratings today said that it believes the impacts of the cuts to the 340B Drug Pricing Program on not-for-profit hospitals that rely on 340B drug savings will likely weaken their operating performance at a time of already tightening margins. This could lead to negative rating actions if hospital-specific funding reductions were material … Read More
Cuts to the 340B program threaten rural hospitals
As leaders in Washington debate ways to lower prescription drug prices, it’s important to remember that many Americans are getting access to free or heavily discounted care through the crucial 340B drug pricing program. This is especially true in rural communities such as here in Boone County in central Iowa, where access to high-quality care is often threatened by economic … Read More
Commentary: Attacks on 340B program distract from source of drug-pricing problem
By Dr. Bruce Siegel Given all the good things hospitals accomplish thanks to 340B Drug Pricing Program savings—from affordable medications to comprehensive services for the poor—it might seem odd the program has taken so much heat lately. But if you consider the larger context of the attacks—the national debate on runaway drug prices—you’ll understand why drugmakers have worked so hard … Read More
May 15 Hearing on 340B
CONSUMER GROUPS BACK 340B — More than 60 patient groups are urging congressional leaders to support the federal drug discount program that’s been the subject of intensifying congressional scrutiny ahead of another Senate HELP Committee hearing this morning. Families USA, Doctors for America, Public Citizen and others write that they “welcome vigorous oversight” but are urging lawmakers to “reject any proposals that weaken this important … Read More